… in breast cancer with nab-paclitaxel are listed in Table 4. … Besides breast cancer, nab-paclitaxel
is being investigated in a … lung cancer (NSCLC) has demonstrated that nab-paclitaxel at …

… II trials of nab-paclitaxel in metastatic breast cancer are … the optimal dosing strategy for
nab-paclitaxel. The trial included … : nab-paclitaxel 300 mg/m 2 every 3 weeks, nab-paclitaxel 100 …

… Nab-paclitaxel has already been approved in 42 countries for the treatment of metastatic
breast cancer … most relevant knowledge on nab-paclitaxel for treating breast cancer in terms of …

… ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab
plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until …

… nanoparticle albumin-bound (NAB)–paclitaxel significantly … sb) paclitaxel followed by
epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast cancer (…

… in the USA, 3-weekly nab-paclitaxel induced a higher response rate and … -paclitaxel in
patients with metastatic breast cancer. Except for grade 3 sensory neuropathy, nab-paclitaxel was …

… In patients with metastatic breast cancer (MBC), nab-paclitaxel … paclitaxel. This phase II
study examined the antitumor activity and safety of weekly and every 3 week (q3w) nab-paclitaxel …

… paclitaxel with nab-paclitaxel. This finding, and the fact that the new checkpoint inhibitors
currently being tested in breast cancer will be given with nab-paclitaxel (… breast cancer therapy. …

… breast cancer and is approved for use in this setting. Increasing evidence suggests that
nab-paclitaxel … Indeed, results of Phase II/III studies indicate that nab-paclitaxel may be effective …

… of nab-paclitaxel may not be the best treatment approach for unselected patients with metastatic
breast cancer, … The growing number of nab-paclitaxel trials in breast cancer will lead to …